Skip to content
Calculator
Compare

BPC-157 vs GHK-Cu

Last updated: November 4, 2026 · 6 min read · By the Grey Peptides Editorial Board

Detailed view of laboratory equipment and pipette in use, enhancing scientific research
Photo by Jess Loiterton on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • BPC-157 is promoted for injuries and the gut, on the strength of rodent studies. GHK-Cu is promoted for skin and collagen, and its human studies are creams applied to skin.
  • Neither has a controlled human trial of injection, which is how both are sold in blends.
  • BPC-157 got a favourable but non-binding compounding vote in July 2026; injectable GHK-Cu is due before a second FDA committee by February 2027. Both are prohibited in sport.

Side by side

BPC-157 Low and GHK-Cu Medium are both graded low on our evidence scale. The table is read from our encyclopedia entries.

FieldBPC-157GHK-Cu
Encyclopedia entryBPC-157 Full entryGHK-Cu Full entry
Molecule classPeptidePeptide
CategoryHealing & RecoveryHealing & Recovery
FDA statusResearch ChemicalResearch Chemical
Approved elsewhereNone recordedNone recorded
Evidence gradeLowMedium
Half-lifeShort systemic half-life (minutes) but prolonged tissue effectUndetermined (systemic)
FormulaC62H98N16O22C14H23CuN6O4
Molecular weight1,419.5 g/mol402.9 g/mol
WADA 2026Prohibited at all times (S0)Prohibited (S0 catch-all)
WADA 2027Prohibited at all times (S0)Prohibited (S0 catch-all)
In one lineA synthetic pentadecapeptide from gastric protein, widely studied in animal models for tendon, ligament, and gastrointestinal healing.A copper-binding tripeptide found in human plasma and sold widely in skin care; the evidence is mostly cell and animal work, with few trials in people.
MechanismBPC-157 promotes angiogenesis via upregulation of VEGFR2 expression and activation of the Egr-1/NAB2 pathway, modulates nitric oxide signaling, and interacts with the dopaminergic and serotonergic systems in animal models. Effects are observed on tendon, ligament, muscle, bone, gastrointestinal tissue, and the blood-brain barrier. Despite extensive preclinical literature, no peer-reviewed human efficacy trials have been published as of 2026.GHK-Cu upregulates expression of genes involved in tissue remodeling, collagen and glycosaminoglycan synthesis, and antioxidant defense. It modulates the expression of decorin, integrins, and fibroblast growth factors, and has been shown in genomic studies to reverse multiple age-related gene expression changes. The copper cofactor is essential for lysyl oxidase activity in collagen cross-linking.
Sources in the entry2423
Study cards2115
Dosage pageDosage pageDosage page

Two very different molecules

BPC-157 is a synthetic 15-amino-acid peptide 1 that the Zagreb research group behind it calls a stable gastric pentadecapeptide; that group has published many of its studies, on gut, tendon, ligament, muscle and bone healing in animals 2.

GHK-Cu is three amino acids, glycine, histidine and lysine, bound to a copper ion. GHK occurs naturally in blood, and the peptide competes with albumin to carry copper 3 4. It is an ingredient in cosmetic 'copper peptide' creams, and FDA's compounding lists treat injectable GHK-Cu separately from other routes 5.

BPC-157's evidence

BPC-157's case rests on animal studies. A 2025 orthopaedic systematic review found 36 eligible studies, 35 of them preclinical, showing improved healing in animal models of muscle, tendon, ligament and bone injury 6. In people, a two-person pilot found intravenous infusions tolerated without changes in standard blood markers 7, a single-clinic chart review of knee injections in 16 patients, reached by phone, had no control group 8, and a bladder-injection pilot in 12 women had none either; a 2026 systematic review that searched to June 1, 2026 found these three studies, 30 people in all, of poor quality 9. FDA's May 2026 briefing counts five clinical studies, about 108 people, adding two older enema studies, one in healthy volunteers and a randomised, placebo-controlled study in ulcerative colitis reported only as a 2005 meeting abstract, whose data FDA judged inadequate 10. A September 2026 report described three dental patients given BPC-157 by injection with TB-500, ARA-290 and other drugs, without a control group 11.

GHK-Cu's evidence

GHK-Cu's human evidence is topical. In a randomised trial of skin care after carbon dioxide laser resurfacing, 13 patients completed the study; computer analysis and blinded evaluators found no faster fading of redness and no difference in wrinkles between groups, although patients rated their skin quality higher with GHK-Cu 12. In animals, injected GHK-Cu increased collagen in implanted wound chambers in rats 13, reduced knee laxity after ligament reconstruction in rats 14, and reduced lung scarring in mice 15. No human study has tested GHK-Cu injected 1.

Why they end up in the same vial

Both are sold for 'healing', and they turn up in the same vial: in the four-peptide blend our blend page describes, GHK-Cu (50 mg) is five times the amount of BPC-157 (10 mg). That makes the comparison practical. A person drawing a blend for its BPC-157 receives five times as much GHK-Cu, a peptide whose human evidence comes from skin creams. Our four-peptide blend page sets out the arithmetic, and no study has tested the two together.

Regulatory and sport status

Neither is FDA-approved. In July 2026, FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157 to the list of substances pharmacies may use in compounding, as reported (FDA has posted no tallies) 16; FDA had not acted on that as of October 27, 2026 5. GHK-Cu's position is split: non-injectable GHK-Cu is in FDA's Category 1 for compounding, while injectable GHK-Cu cannot be compounded and is due before a second committee meeting by the end of February 2027 5. Our article on the second PCAC five covers what that meeting will consider. Both are prohibited at all times under the WADA Code, BPC-157 by name and GHK-Cu under the catch-all for non-approved substances 1.

On October 30, 2026, HHS, FDA's parent department, published a notice saying it will not take enforcement action against 503A pharmacy compounding of BPC-157 under the forms, routes and conditions in its Appendix B 17. The policy is non-binding, labelled a draft and open to revision; FDA has not added it to the 503A Bulks List or Category 1, and the policy does not cover research-use-only sales (our fact check).

Safety questions

Neither peptide has a long-term human safety record by injection. In animal studies BPC-157 promotes blood-vessel growth 2, which raises questions for people with a history of cancer; our article on BPC-157 and angiogenesis sets out the evidence. GHK-Cu delivers copper, and while topical use has a long cosmetic history, injected GHK-Cu has not been studied in people 1.

How the differences add up (as of October 27, 2026)

If the question is skin, GHK-Cu has small topical human studies with mixed results; BPC-157 has none. If the question is injuries, BPC-157 has a large animal literature and a handful of small human studies, none a fully published controlled trial 9 10; GHK-Cu has a few animal injury studies. For injected use, which is how both are sold, neither has a controlled human trial. Our ranking of peptides for tendon and ligament injuries puts both in context.

Frequently asked questions

What is the difference between BPC-157 and GHK-Cu?

BPC-157 is a synthetic 15-amino-acid peptide, described by its originators as a gastric pentadecapeptide, promoted for injuries and gut healing; GHK-Cu is a copper-binding tripeptide promoted for skin and collagen. Their evidence comes from different kinds of study.

Which is better for healing?

Neither has a controlled human trial of injection. BPC-157 has many rodent injury studies; GHK-Cu's human studies are topical skin studies with mixed results.

Can you take BPC-157 and GHK-Cu together?

They are combined in commercial blends, but no study has tested them together in people or animals, and the four-peptide blend we describe holds five times as much GHK-Cu as BPC-157.

Sources

  1. Grey Peptides dataset records for BPC-157 and GHK-Cu (status, WADA 2026 and 2027 status, studied doses as sourced on each entry; no human injection study of GHK-Cu); read October 27, 2026.
  2. Seiwerth, S., et al. (2018). BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des, 24(18), 1972-1989. PMID: 29998800
  3. Lau, S. J., et al. (1981). The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochem J, 199(3), 649-56. PMID: 7340824
  4. Bossak-Ahmad, K., et al. (2021). Ternary Cu(2+) Complexes of Human Serum Albumin and Glycyl-l-histidyl-l-lysine. Inorg Chem, 60(22), 16927-16931. PMID: 34730942
  5. U.S. Food and Drug Administration. July 23-24, 2026 Pharmacy Compounding Advisory Committee (no minutes or vote tallies posted); GHK-Cu (injectable) due at a second meeting before the end of February 2027; FDA 503A category list updated May 14, 2026 (non-injectable GHK-Cu in Category 1). Re-read October 3 and October 27, 2026.
  6. Vasireddi, N., et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J, 21(4), 485-495. PMID: 40756949
  7. Lee, E., et al. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med, 31(5), 20-24. PMID: 40131143
  8. Lee, E., et al. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med, 27(4), 8-13. PMID: 34324435
  9. Poolton, J. T., et al. (2026). Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg, 92(3). PMID: 42885452
  10. U.S. Food and Drug Administration. FDA Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), briefing document for the July 23-24, 2026 Pharmacy Compounding Advisory Committee, dated May 11, 2026: five clinical studies found in PubMed and Embase (rectal enemas in 24 healthy subjects; a multicentre, randomised, double-blind, placebo-controlled enema study in ulcerative colitis, 53 randomised, reported only as a 2005 meeting abstract, its data judged inadequate to support efficacy or safety; intra-articular injections in 17 people with knee pain; an intravesical injection in 12 with interstitial cystitis; intravenous infusions in 2 healthy subjects), 108 people by its own counts. Read October 28, 2026. FDA
  11. Froum, S., et al. (2026). Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health, 7, 1907109. PMID: 42876687
  12. Miller, T. R., et al. (2006). Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 8(4), 252-9. PMID: 16847171
  13. Maquart, F. X., et al. (1993). In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest, 92(5), 2368-76. PMID: 8227353
  14. Fu, S. C., et al. (2015). Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res, 33(7), 1024-33. PMID: 25731775
  15. Ma, W. H., et al. (2020). Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways. Life Sci, 241, 117139. PMID: 31809714
  16. McDermott (law firm). Bulk-list bound? PCAC backs majority of peptides in two-day public meeting (July 27, 2026): tallies for all seven. Read October 27, 2026; FDA has posted no minutes or tallies. Other reports agree on every tally except epitalon's 'no' count (7-4-1 here and in the FDA Law Blog; 7-5-1 in RAPS Regulatory Focus). Cited without a link.
  17. US Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026; docket HHS-OASH-2026-0496 (non-binding; labelled a draft). Read November 4, 2026. Federal Register

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All comparisons

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead